Traders should monitor the rescheduled call for any updates on clinical progress, funding, or pipeline developments. The delay itself is not material, but the subsequent report may contain actionable data.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $3.40entry
- T+1 · 9mo ago −5.29%α −3.98% · $3.22
- T+5 · 8mo ago +22.94%α +25.18% · $4.18
- T+20 · 8mo ago +11.18%α +14.97% · $3.78
- T+60 · 6mo ago +14.71%α +3.41% · $3.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion delayed the filing and publication of its 2025 annual report due to technical issues with external vendors, not related to the content of the report. As a result, the earnings conference call has been rescheduled to March 6, 2026. The company emphasized that the delay is administrative and does not reflect any issues with financial or operational results.
Key Facts
- Evaxion delayed the release of its 2025 annual report due to technical issues with external regulatory filing vendors.
- The delay is administrative and unrelated to the report's content.
- The earnings conference call was rescheduled from March 5 to March 6, 2026, at 8:30 AM ET.
- Investors must register in advance to participate in the call and receive a PIN.
- The webcast will be available live and recorded on the company’s website.
Financial Impact
No immediate financial impact, delay is technical and temporary.
Risk Factors
- Perception risk: Repeated delays or technical issues could raise concerns about operational reliability.
- Information asymmetry: Material news might be delayed until the report is published.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250121 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers